Background {#Sec1}
==========

The 1968 Yusho poisoning accident affected over 1800 people in western Japan \[[@CR1]\]. Since the Yusho outbreak, the National Study Group for the Therapy of Yusho has carried out medical care and health examinations of patients affected \[[@CR2]\]. In 2001, the measurement of PCDDs, PCDFs, and non-*ortho* PCBs in the blood became possible using small amounts of blood collected from participants during annual medical examinations \[[@CR3]--[@CR5]\]. We have measured the concentrations of PCDDs, PCDFs, and dioxin-like PCBs in the blood collected from Yusho patients in medical health examinations since 2002 \[[@CR6]--[@CR8]\]. Moreover, we have conducted a congener-specific analysis of non-dioxin-like PCBs in the blood of these patients since 2004 \[[@CR9], [@CR10]\]. Based on these results, we previously reported that Yusho patients continue to have higher concentrations of PCDFs in their blood than unaffected people, and that concentration of PCDFs in the blood is significantly correlated with the intensity of Yusho symptoms \[[@CR11], [@CR12]\].

Development of effective therapy to reduce the concentrations of PCDDs, PCDFs, and PCBs in the blood of Yusho patients could improve the health care of these patients. With regard to promoting the excretion of lipophilic contaminants stored in the human body, several studies of dietary supplements such as cholestyramine, mineral oil, hexadecane, and dietary fiber have been reported using laboratory animals \[[@CR13]--[@CR16]\]. In addition, another study reported the enhancing effect of non-absorbable lipid substitute olestra on fecal excretion of PCDDs, PCDFs, and PCBs in the human body \[[@CR17], [@CR18]\]. Our study group previously conducted a clinical trial to reduce the concentrations of PCDDs, PCDFs, and PCB in the blood of Yusho patients using cholestyramine and rice bran fiber \[[@CR19], [@CR20]\]. However, beneficial clinical effects could not be confirmed due to the short trial period.

Colestimide, a 2-methylimidozarol-epichlorohydrin polymer, is widely used to lower serum cholesterol levels in Japan. Recently, oral colestimide was reported to lower the concentration of PCDDs, PCDFs, and PCB in the blood of humans \[[@CR21], [@CR22]\]. A pilot study showed that the arithmetic mean total TEQ concentrations of PCDDs, PCDFs, and PCBs in the blood of subjects after the trial decreased approximately 20 % compared to pre-trial levels, suggesting that colestimide could decrease human dioxin levels \[[@CR21], [@CR22]\]. We designed the current clinical trial study based on this information. In this study, we examined whether colestimide could reduce the individual congener concentrations of PCDDs, PCDFs, and PCBs in the blood of Yusho patients.

Methods {#Sec2}
=======

Sampling {#Sec3}
--------

The trial protocol was approved by the institutional ethics committee of Kyusyu University Hospital. Patients who fulfilled the diagnostic criteria for Yusho established by the National Study Group for the Therapy of Yusho were eligible for this study. Patients were recruited at explanatory meetings conducted in Fukuoka and Nagasaki Prefectures. 50 Yusho patients were enrolled in this clinical trial, and 14 patients refused to participate. The remaining 36 patients participated in the trial. Informed consent was obtained for study participation. The patients self-administrated colestimide 3 g/day orally for 6 months. Out of the 36 Yusho patients who participated in the clinical trial, 26 patients completed the trial. The 26 patients ranged in age from 60 to 87 years (mean: 72.9, median: 72.5). Among the 26 patients, there were 13 men (age range 60--87 years; mean: 73.1, median: 74.0) and 13 women (age range 61--81 years; mean: 72.8, median: 72.0). The blood samples examined in this study were collected between April 4, 2008 and July 15, 2009. After collection, the blood samples were stored at 4 °C until analyses.

Materials {#Sec4}
---------

Native congeners of PCDDs, PCDFs, dioxin-like PCBs, and non-dioxin-like PCBs were purchased from Wellington Laboratories (Guelph, Canada). \[^13^C~12~\]--congeners of PCDDs, PCDFs, dioxin-like PCBs, and non-dioxin-like PCBs as internal standards, were also purchased from Wellington Laboratories. An active carbon column was prepared as follows: active carbon was purchased from Nacalai Tesque (Kyoto, Japan), refluxed 3 times with toluene for 1 h, and dried in vacuum, after which 500 mg of the active carbon was mixed with 500 g of anhydrous sodium sulfate (Wako Pure Chemical Industries, Ltd., Tokyo, Japan). A silver nitrate/silica gel was purchased from Wako Pure Chemical Industries, Ltd. All reagents and solvents used in this experiment were of the analytic grade of dioxin that is commercially available.

Analysis of PCDDs, PCDFs, and PCBs {#Sec5}
----------------------------------

The extraction and purification of PCDDs, PCDFs, dioxin-like PCBs, and non-dioxin-like PCBs from blood samples were performed using a previously reported method \[[@CR5], [@CR9]\]. Concentrations of PCDDs, PCDFs, and dioxin-like PCBs and concentrations of 58 non-dioxin-like PCB congeners were determined by a previously reported method \[[@CR5], [@CR9]\].

Quality control {#Sec6}
---------------

To evaluate the accuracy and reliability of the analysis of PCDDs, PCDFs, dioxin-like PCBs, and non-dioxin-like PCBs, our laboratory prepared human blood samples and conducted quality control studies of the analysis of PCDDs, PCDFs, and dioxin-like PCBs in 2007, 2009, 2011, and 2013 and non-dioxin-like PCBs in 2008, 2010, 2012, and 2014. Each quality control study involved the participation of various laboratories that perform measurements for these compounds in human blood in Japan. In each quality control study, our results were compared with those of participating laboratories, and tests confirmed that the average variation among values obtained by each organization performing the analysis was all within 10 %. These results indicated that our laboratory's analytical methods regarding PCDDs, PCDFs, dioxin-like PCBs, and non-dioxin-like PCBs in human blood provided accurate results.

Data analysis {#Sec7}
-------------

To estimate the TEQ concentrations, we introduced ND (less than the detection limit) values to half values of the detection limit and calculated based on the TEF values proposed by the WHO \[[@CR23]\]. The statistical analysis was conducted using Wilcoxon signed-rank test in the software programs from Statistics Package for Social Sciences (version 22; IBM Armonk, NY, USA). Significant probabilities (*p* values) were calculated for the respective number of samples analyzed.

Results {#Sec8}
=======

The objective of the present study was to evaluate the effectiveness of colestimide on the individual congener concentrations of PCDDs, PCDFs, and PCBs in blood of Yusho patients. Of the 36 Yusho patients who began the trial, 9 patients stopped administrating colestimide due to serious adverse effects, constipation or abdominal distension. Of the 27 remaining patients, we failed to collect a posttreatment blood sample from one patient due to cancellation of hospital visit. The individual congener concentrations of PCDDs, PCDFs and PCBs in the blood of 26 Yusho patients before the trial were compared with those after the trial (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}).Table 1Effect of colestimide on the individual congener concentrations of PCDDs, PCDFs, and dioxin-like PCBs in the blood of Yusho patientsCongenersConcentration (pg/g lipid)*p* ValuesBefore the clinical trialAfter the clinical trialMeanMedianSDMinimumMaximumMeanMedianSDMinimumMaximum2,3,7,8-TetraCDD1.81.70.90.54.02.01.81.20.54.70.0831,2,3,7,8-PentaCDD14144.96.62314126.16.1270.6751,2,3,4,7,8-HexaCDD3.13.01.71.07.13.33.21.71.06.90.0531,2,3,6,7,8-HexaCDD62533616183635534151640.2581,2,3,7,8,9-HexaCDD5.54.55.22.1295.73.96.01.0310.7701,2,3,4,6,7,8-HeptaCDD55472521113524327201430.137OctaCDD69960628132332667054330930516100.118Total PCDD841739315413152581168834638218500.1442,3,7,8-TetraCDF2.82.71.30.55.52.72.61.40.55.80.4271,2,3,7,8-PentaCDF1.31.10.90.53.51.51.21.10.54.40.5542,3,4,7,8-PentaCDF24119115848636242205158496130.7321,2,3,4,7,8-HexaCDF6451567.82276452568.12070.9901,2,3,6,7,8-HexaCDF2621196.2862622195.2740.5342,3,4,6,7,8-HexaCDF1.21.00.71.03.41.21.00.61.03.41.0001,2,3,7,8,9-HexaCDFNDND1,2,3,4,6,7,8-HeptaCDF2.21.01.51.06.52.31.01.81.07.80.8201,2,3,4,7,8,9-HeptaCDFNDNDOctaCDFNDNDTotal PCDF34228022971963344292230718900.73233\'4\'4\'-TriCB(\#77)6.95.03.75.0168.97.54.35.0200.016344\'5-TriCB(\#81)5.35.01.45.0125.75.02.45.0150.18033\'44\'5-PentaCB(\#126)12910081303911319685343560.77033\'44\'55\'-HexaCB(169)2792501441046782932801291145850.101Total Non-ortho PCBs4203821781839064394061661967890.078233\'44\'-PentaCB(\#105)4454314535551206137884581323637145.0152280.5012344\'5-PentaCB(\#114)2800236516885.071942997268116995.069870.11823\'44\'5-PentaCB(\#118)2171816568176015.0754752105015412143354575572600.9902\'344\'5-PentaCB(\#123)3042282735.012393122142375.08980.581233\'44\'5-HexaCB(\#156)5047232661463751307919501751038307414366795281801630.517233\'44\'5\'-HexaCB(\#157)13157808813150339053954127477644115202332469940.99023\'44\'55\'-HexaCB(\#167)4834424333735.016863461042652422985104810.770233\'44\'55\'-HeptaCB(\#189)7385510058881664244297398539753231730224340.829Total Mono-ortho PCBs1051258347266740400662930771047349365959308347462672730.829TEQ from PCDDs24247.9114324249.211420.809TEQ from PCDFs82635416223826854162110.534TEQ from PCDDs/PCDFs1068360272651078761282490.790TEQ from non-*ortho* PCBs21209.87.45422209.77.8470.485TEQ from mono-*ortho* PCBs3.22.52.01.28.83.12.81.81.08.00.829TEQ from dioxin-like PCBs2422119.0602523119.1510.603Total TEQ130120654230313211765432830.869ND (less than the detection limit) values introduced to half values of the detection limit and calculated the TEQ concentrations*SD* standard deviation, *CDD* chlorinated dibenzo-p-dioxin, *CDF* chlorinated dibenzofuranTable 2Effect of colestimide on the individual congener concentrations of non-dioxin-like PCBs in the blood of Yusho patientsIUPAC\#Concentration (pg/g lipid)*p* ValuesBefore the clinical trialAfter the clinical trialMeanMedianSDMinimumMaximumMeanMedianSDMinimumMaximumTriCB-28164414498663243809183718661226561870.025TriCB-29201218572205235990.845TriCB-371285245584773516556980.112TeteraCB-443482485235284141532441510722610.034TeteraCB-47/48525359437117176964047171512136590.049TeteraCB-49295179409441679344216576530700.101TeteraCB-52/699567808362944572106086074536838960.052TeteraCB-56/604423063445141248928457710430100.889TeteraCB-631161176552801401186953600.382TeteraCB-66211815201507586585321811536169161384750.551TeteraCB-7036213080713337541814313085568170.280TeteraCB-7137115652381265490525240.586TeteraCB-7414823127209202383041089145051187590682973351940.770PentaCB-8524713933551592205138218510860.657PentaCB-8781279744851716747697442520590.183PentaCB-9271957148252402752669455522640.412PentaCB-93/95/98727637439519641003746116532664280.258PentaCB-992362319114174534240906852487323328166344308821510.182PentaCB-1011931153412345566723371959148160069150.174PentaCB-107/10896378570753340961819584524350.166PentaCB-11033924232551451332298268514280.638PentaCB-1171911146618134357951172213061642565790.280HexaCB-12892568566053099949678775538990.443HexaCB-1307065560357802080251227238588655781913252580.568HexaCB-13239932625251125445397282511340.143HexaCB-1342555051833554751680.203HexaCB-13541934231851577485330403515870.382HexaCB-137105657132906629964124410646778687342336399910.889HexaCB-13896984891635296725546240863976858430653897233812446470.990HexaCB-139/149635452619152404615292696523030.568HexaCB-14132825524651044340282287511690.716HexaCB-14632968342201634611603831493521131688162629839689360.086HexaCB-14772456746351678768622519518060.527HexaCB-15113299818804283402134910081098542650.258HexaCB-15320092918417610610973832516088206380180663109234593144587430.501HexaCB-163/1644879747157251681742611357749567478722273815767885520.694HexaCB-165NDNDHeptaCB-1706970460801395231640319428969053626453707199461429220.829HeptaCB-172994792735381276827207101561055352775203650.354HeptaCB-17715845145139212450439642163591468199322598404960.424HeptaCB-1781588513134117885562111720913068111233710429450.012HeptaCB-17928118229651110357202384514630.005HeptaCB-18020577920127213697150473703408203297188508121684327444909340.970HeptaCB-18155329267152776581296716528060.264HeptaCB-182/18776063606846102814834270253818456104663293140932385870.019HeptaCB-1831684314980120054733450121786415557132923756557880.182HeptaCB-1913078292220085866729072762168880575610.280OctaCB-19431774322932277651166753251932465194278258842190.304OctaCB-1957832683555945261807929715647761879195640.381OctaCB-196/203171071513811346555263168211531293314346386170.869OctaCB-198/201147711253611520556995143681182986734251342630.534OctaCB-20065948560752350705593609524490.083OctaCB-2025432389345325225695298389233071509125500.258OctaCB-2059778986335279596991245628919490.770NonaCB-2065049456128291502148744891463924465107260.657NonaCB-20792275557252501911792522519050.326NonaCB-2081877173112095633818271723953545590.778DecaCB-2091857159889089351151900194673083740050.200Total TrCBs17921471999334392119311917119870862250.182Total TeCBs2002317013112466548506192031816713113515981431940.424Total PeCBs31271260271994571371026933293231001190767680932100.228Total HxCBs4020983731411967921529768923164117183583441986641315397690400.675Total HpCBs4139794012852653641051261341206419627378119250647807749718400.620Total OcCBs78553775495560535281931786087710144919214771869480.409Total NoCBs78496439441623552371276297224383215171590.869Total DeCBs1857159889089351151900194673083740050.200Total PCBs957422871523520304320807264255597466480628949508928608820068170.585ND (less than the detection limit) values introduced to half values of the detection limit and calculated the TEQ concentrations*SD* standard deviation, *CB* chlorinated biphenyl

The arithmetic mean TEQ concentrations of PCDDs, PCDFs, non-*ortho* PCBs, and mono-*ortho* PCBs in the blood of the 26 Yusho patients were 24, 82, 21, and 3.2 pg TEQ/g lipid, respectively, before the trial, and 24, 82, 22, and 3.1 pg TEQ/g lipid, respectively, after the trial. Total TEQ concentration of these dioxin-like compounds equaled 42--303 (mean: 130, median: 120) pg TEQ/g lipid before the trial, and 43--283 (mean: 132, median: 118) pg TEQ/g lipid after the trial, indicating that the concentrations before the trial were almost the same as those after the trial. Regarding the non-dioxin-like PCB concentrations, the sums of the concentrations of 58 PCB congeners in the blood before and after the trial were 321--2643 (mean: 957, median: 872) and 286--2007 (mean: 975, median: 806) ng/g lipid, respectively. The arithmetic mean concentrations of triCBs, tetraCBs, pentaCBs, hexaCBs, heptaCBs, octaCBs, and nonaCBs in the blood of Yusho patients were 1.8, 20, 31, 402, 414, 79, and 7.8 ng/g lipid, respectively, before the trial, and 1.9, 20, 33, 412, 420, 79, and 7.6 ng/g lipid, respectively, after the trial, indicating that concentrations of these PCBs compounds were also almost the same before and after the trial. These results indicated that the concentrations of PCDDs, PCDFs, dioxin-like PCBs and non-dioxin-like PCBs in the blood of Yusho patients were not significantly altered by the intervention with oral colestimide.

We previously reported that the concentrations of 1,2,3,6,7,8-hexaCDD, 2,3,4,7,8-pentaCDF, 1,2,3,4,7,8-hexaCDF, 1,2,3,6,7,8-hexaCDF, hexaCB-169, hexaCB-156, hexaCB-157, and heptaCB-189 in the blood of Yusho patients were higher than those of the normal controls \[[@CR8], [@CR9]\]. These can be considered the characteristic congeners in the blood of Yusho patients. 2,3,4,7,8-PentaCDF is recognized as the most important causative agent for subjective symptoms of Yusho. Blood levels before and after the trial were 48--636 (mean: 241, median: 191) and 49--613 (mean: 242, median: 205) pg TEQ/g lipid, respectively, indicating that the concentration did not significantly decrease with administration of colestimide. This was also the case for the concentrations of other characteristic congeners before and after the trial. Among congeners of PCDDs, PCDFs, dioxin-like PCBs, and non-dioxin-like PCBs, most congeners did not show statistically significant differences. According to these results, the therapeutic usefulness of colestimide in reducing the concentrations of PCDDs, PCDFs, and PCBs in blood of Yusho patients could not be confirmed.

Discussion {#Sec9}
==========

Over 48 years have passed since the outbreak of Yusho disease. However, some patients are still afflicted with intractable symptoms such as chloracne, general fatigue and neuropathy \[[@CR12]\]. There are patients who continue to have much higher concentrations of dioxin-like compounds in their blood than unaffected persons. Moreover, the half-lives of blood concentrations of 2,3,4,7,8-pentaCDF have become long to near infinity in the majority of Yusho patients \[[@CR24]\]. To reduce the concentrations of PCDDs, PCDFs, and PCBs in the blood of Yusho patients, our study group previously conducted a clinical trial using cholestyramine and rice bran fiber \[[@CR19], [@CR20]\]. Results of that study showed that the amounts of 2,3,4,7,8-pentaCDF in patients' feces actually increased, although beneficial clinical effects were not apparent, possibly due to a short trial period. A recent study reported that colestimide can decrease the concentrations of PCDDs, PCDFs, and PCBs in blood \[[@CR21], [@CR22]\]. Eight male and two female healthy subjects were treated with colestimide (3 g/day) for 6 months. In this report, colestimide was effective for promoting excretion of dioxin-like compounds from the human body. Colestimide is a non-absorbable anion exchange resin and enhances excretion of cholesterol in feces by inhibiting absorption of food-derived cholesterol in the intestinal tract \[[@CR25]\]. Based on this result, we designed a clinical trial with colestimide for Yusho patients. However, in the present study, we were unable to confirm a significant decrease in most congeners of PCDDs, PCDFs, and PCBs in the blood of Yusho patients. It is suggested that the PCDDs, PCDFs, and PCBs that have remained in the whole body of patients over the 45 years since the outbreak of Yusho are very difficult to excrete from the body. In the present trial, there may be many limitations such as a small number of participants, duration of administration period and dose of cholestimide. Out of the 36 patients who participated in the trial, 9 patients experienced serious adverse effects (constipation or abdominal distension) by the repeated administration of colestimide. Therefore, we cannot recommend that elderly patients participate in clinical trial studies for such long periods as in the present study.

Conclusion {#Sec10}
==========

Although over 48 years have passed since the outbreak of Yusho, many patients still suffer various symptoms such as chloracne, general fatigue and neuropathy. The concentrations of causative dioxin-like compounds in their blood remain at high levels. We examined whether oral administration of colestimide could reduce the concentrations of PCDDs, PCDFs, and PCBs in the blood of Yusho patients. However, the effectiveness of colestimide on the concentrations of these dioxin-like compounds in the blood of Yusho patients could not be confirmed.
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